Program Schedule - ISCT 2025 New Orleans

Message Image

Skip main navigation (Press Enter).

The Full Program provides you with a robust preview of all event sessions you can experience at ISCT 2025 New Orleans.

Explore a selection of exclusive ISCT programs tailored to immerse you in the latest advancements in cell and gene therapy.

Translational Pathway Program
25 plenary and concurrent sessions in which global key opinion leaders are invited to present novel research, data, and ideas that will shape the future of the cell and gene therapy translation sector.

Roundtable Program
50 workshop-like sessions that leverage the interdisciplinarity and depth in expertise of ISCT delegates to tackle pressing practical problems facing the cell and gene therapy translation sector and provide a platform to collaborate on timely practical solutions.

Abstracts
Be considered for an oral abstract, elevator pitch, or poster presentation to showcase your work to global leaders, key opinion leaders, potential collaborators, and future employers in the cell and gene therapy sector.

Global Showcase Presentations
Fast-paced and engaging presentations that provide a platform for ISCT partners to showcase their distinctive features, cutting-edge products, and innovative technologies.

Corporate Sessions
Educational sessions organized by ISCT partners to explore important topics and emerging trends within the rapidly evolving landscape of cell and gene therapy.

Laboratory Practice Essentials
Presented by the ISCT Lab Practices Committee, this track features 8 thoughtfully designed concurrent sessions led by laboratory experts, covering essential topics such as tools, techniques, and personnel training for laboratory professionals.

Click on the image below to view the
ISCT 2025 Program at a Glance:

VIEW THE FULL PROGRAM FOR:

Please note that the following schedule are still subject to changes.

TUESDAY, MAY 6, 2025

Register Now →

WEDNESDAY, MAY 7, 2025

07:00

07:00-08:00

CORPORATE SESSION

Improving Cell Therapy Manufacturing Robustness with Real-Time Analytics

08:00

08:00–09:00
BASIC & DISCOVERY RESEARCH

Uncommon Starting Materials - Navigating Uncertainty to Evaluate Benefits

08:00–09:00
BASIC & DISCOVERY RESEARCH

ROUNDTABLE

What Really Are Mesenchymal Stromal Cells?

08:00–09:00
REGULATION & POLICY

Learning from Clinical Trial Failures - The Case of Viral Specific Cytotoxic T Lymphocytes

08:00–09:00
BIOPROCESSING & MANUFACTURING

Optimizing Viral Vector Manufacturing: Designing Efficient Facilities Within Constraints

08:00–09:00
BIOPROCESSING & MANUFACTURING

Investing In Your Manufacturing - Implementation Hurdles for PATs in CGTs

08:00–09:00
REGULATION & POLICY

How to Optimize Cell Procurement for Multiple Geographies and End Uses?

08:00–09:00
CLINIC & THERAPEUTIC DEVELOPMENT

Safety versus Scalability - The Allogeneic iPSC Problem

09:00

09:30

09:15–10:15
CLINIC & THERAPEUTIC DEVELOPMENT

Will MSC-EVs Fare Better Than MSCs?

09:15–10:15
REGULATION & POLICY

Overcoming the Clinical Trial Bottleneck - Designing Studies With Site Constraints in Mind

09:15–10:15
COGS & BUSINESS MODELS

Gene Therapy Hurdles on the Road from Approval to Global Adoption

09:15–10:15
BIOPROCESSING & MANUFACTURING

What Value Does Your QC Process Add?

09:15–10:15
REGULATION & POLICY

Donors - The Allogeneic Problem

09:15–10:15
BIOPROCESSING & MANUFACTURING

Scaling Cell Therapy Manufacturing to Treat the Rapidly Expanding Patient Populations

09:15–10:15
REGULATION & POLICY

Can We Ever Deviate From the RCT Gold Standard?

10:00

10:15-10:45

COFFEE BREAK

SUPPORTED BY:

10:45–11:45
REGULATION & POLICY

Politics and Health - How Can Political Administrations Really Impact the CGT Sector?

10:45–11:45
BIOPROCESSING & MANUFACTURING

Decentralized Manufacturing - New Technologies and Strategies

10:45–11:45
REGULATION & POLICY

End of FDA's Enforcement Discretion Period - What Does It Mean For Your Lab Developed Tests?

10:45–11:45
BIOPROCESSING & MANUFACTURING

How to Freeze in the Cold Chain?

10:45–11:45
TOOLS & TECH

Preparing for AI: Automating Manufacturing of iPSC-Based Therapies

10:45–11:45
REGULATION & POLICY

Beyond One Label: Accelerated Approvals and Risk Considerations for Cell & Gene Therapies

10:45–11:45
REGULATION & POLICY

Are Your Raw Materials Regionally Ready? Exploring the Global Landscape of Raw Material Quality and Regulatory Guidelines for Cell and Gene Therapies

11:00

11:45-13:00

LUNCH
in Exhibit Hall, Level 1

12:00

12:00-13:00

ELEVATOR
PITCH PRESENTATIONS

12:00-13:00

CORPORATE SESSION

Enabling Today's Solutions to Shape the Future of Cell Therapy Manufacturing

12:00-13:00

CORPORATE SESSION

Accelerating Cell Therapy Development Through the Power of Strategic Collaborations

12:00-13:00

CORPORATE SESSION

How Next Generation Technologies and Services are Enabling Widespread Patient Access to Cell and Gene Therapies

GLOBAL SHOWCASE
Theater A

12:00–12:15
Scaling the future of Cell Therapy: Advancing iPSC CLD & Manufacturing to enhance patient access
Learn More →

12:15–12:30
A serum-free, chemically defined workflow GMP solution for the development & manufacturing of Mesenchymal Stem Cell-based therapeutic products
Learn More →

12:30–13:45
Harnessing Predictive Analytics: The Transformative Power of Laser Force Cytology™ in Cell Therapy Workflows
Learn More →

12:45–13:00
Revolutionizing CAR-T Manufacturing: A New Era in T Cell Expansion
Learn More →

GLOBAL SHOWCASE
Theater B

12:45-13:00
Precision Logistics:
A Patient-First Model for Advanced Therapies
Learn More →

13:00

13:00–14:00
REGULATION & POLICY

Balancing Global Regulatory Convergence Efficiencies Against Unique Regional Requirements

13:00–14:00
REGULATION & POLICY

Can Point-of-Care Manufacturing Meet Regulatory Requirements?

13:00–14:00
CLINIC & THERAPEUTIC DEVELOPMENT

Cell Therapies to Manage GvHD - Learning From Pivotal Approvals

13:00–14:00
GLOBAL CGT MARKETS

Regulating Clinical Access to Unapproved and Unproven Cell Therapies - Lessons From APAC

14:00

14:15–15:15
REGULATION & POLICY

Is Germline Editing Feasible and Should it be Permissible?

14:15–15:15
CLINIC & THERAPEUTIC DEVELOPMENT

Enabling Patient Access - Preparing Local Sites for the CGT Wave

14:15–15:15
CLINIC & THERAPEUTIC DEVELOPMENT

Viral Vector: Topic to be announced

14:15–15:15
TOOLS & TECH

Can Advanced Analytics with Data-driven Manufacturing Power Up Cell Therapy?

14:15–15:15
GLOBAL CGT MARKETS

Cheaper CAR Ts - Can They Be Replicated?

14:15–15:15
REGULATION & POLICY

Harmonizing cGMP Standards in APAC to Lower Costs

14:15–15:15
REGULATION & POLICY

The Global Approval Pathway - Realistic Solution or Distant Utopia?

15:00

15:15-15:45

COFFEE BREAK

SUPPORTED BY:

15:00-16:30

CORPORATE SESSION

Bringing Cell and Gene Therapies to Market: Overcoming Challenges in Manufacturing, Analytics, and Scaling for Success

16:00

16:15-17:00

WELCOME ADDRESS & MAJOR AWARDS PRESENTATION

17:00

17:00-18:30

18:00

18:30

18:30-20:30

WELCOME RECEPTION

in Exhibit Hall

19:00-20:30

POSTER NETWORKING
RECEPTION 1

Immunotherapy
|(CAR-T, T Reg, NK Cells etc.)

Embryonic, Organ and
Other Tissue Specific Stem Cells

iPSC

Hematopoietic Stem /
Progenitor Cells and Engineering

Gene Editing / Gene Therapies
(AAVs, LNPs, nucleotide-based therapies)

GLOBAL SHOWCASE
Theater A

More information TBD

GLOBAL SHOWCASE
Theater B

More information TBD

19:00

19:30

20:00

21:00

THURSDAY, MAY 8, 2025

07:00

07:30

07:00-08:00

CORPORATE SESSION

Catalysts of Innovation: How G-Rex® Grant Recipients are Shaping the Future of Cell and Gene Therapy Manufacturing

08:00

08:30

08:00–09:00
SCIENCE & INNOVATION

CONCURRENT

Moving Beyond the Vanilla: Employing Intelligent Therapeutic Design & Manufacturing Automation to Develop Multiple CGT Flavors

08:00–09:00
SCIENCE & INNOVATION

CONCURRENT

Building the Future: Multidimensional Strategies in Organ Regeneration

08:00–09:00
ORAL ABSTRACT

Mesenchymal Stem / Stromal Cells #1

08:00–09:00
LAB PRACTICE ESSENTIALS

Establishing an In-House CAR-T Manufacturing Platform

08:00–09:00
COGS & BUSINESS MODELS

Start-Up Strategies to Bridge the Valley of Death

08:00–09:00

PITCH SESSION 1

09:00

09:30

09:15–10:15
SCIENCE & INNOVATION

CONCURRENT

Beyond Boundaries: The Future of Regenerative Medicine, 3D Bioengineering, and CGT in Space

09:15–10:15
SCIENCE & INNOVATION

CONCURRENT

Advanced Analytics: Harnessing AI and Cutting-Edge Technologies to Accelerate Cell Therapy Development

09:15–10:15
SCIENCE & INNOVATION

CONCURRENT

New Approach Methodologies (NAMs) and Non-Animal Models: How does CGT move forward along with FDA Modernization Act 2.0 and 3.0?

09:15–10:15
ORAL ABSTRACT

Immunotherapy #1 (CAR-T, T REG, NK CELLS, etc.)

09:15–10:15

PITCH SESSION 2

09:15–10:15
LAB PRACTICE ESSENTIALS

Change Implementation: New Standards, Deviations, Occurrences and Validations

09:15–10:15
COGS & BUSINESS MODELS

ROUNDTABLE

Capital Markets 101 - Demystifying Fundraising and Investment Strategies for Your Startup

09:15–10:15
CLINIC & THERAPEUTIC DEVELOPMENT

ROUNDTABLE

Protecting Donors, Saving Patients - Conceptualizing a National Registry

10:00

10:30

10:15-10:45

COFFEE BREAK
in Exhibit Hall

GLOBAL SHOWCASE
Theater A

10:15–10:30
Moving Beyond Minimally Manipulated HCT/P Challenges for MSC Expansion and CAR-T Manufacturing
Learn More →

10:30–10:45
Accelerating Product Development
Learn More →

GLOBAL SHOWCASE
Theater B

10:15–10:45
Effective Manufacturing of Allogeneic Mesenchymal Stem Cells Using a Scalable Closed-system Circulation Platform
Learn More →

10:45-12:15

11:00

11:30

12:00

12:30

12:15-13:45

LUNCH
in Exhibit Hall, Level 1

12:45-13:45

CORPORATE SESSION

Vertical-Wheel Bioreactor: A Scalable, Cost-Effective Solution for PSC Process Optimization and Translation to Clinical Manufacturing

12:45-13:45

CORPORATE SESSION

Bringing iPSCs Closer to Manufacturability

12:45-13:45

CORPORATE SESSION

Developing Ecosystems to Accelerate the Delivery of Cell Therapies to Patients

GLOBAL SHOWCASE
Theater A

12:15–12:30
Scalable T Cell Expansion in Closed Bioreactors: Optimized Manufacturing with GMP ImmunoCult™ Reagents
Learn More →

12:30–12:45
Patient-Derived Organotypic Tumor Spheroids (PDOTS) Optimize Donor Selection in Allogeneic Cell Therapy Development
Learn More →

12:45–13:00
ARES X20+: Revolutionizing Fill and Finish for Cell Therapy
Learn More →

13:00–13:15
Rapid CAR-T cells: Reducing costs and enabling high-throughput production of potent memory CAR-T cell products in an automated 3-day manufacturing process
Learn More →

13:15–13:30
Streamlined Cytokine Delivery for Scalable, Closed System Cell Therapy Manufacturing
Learn More →

13:30–13:45
Generation of T cells from hiPSC with Animal origin-free medium -Stem FitTM for Differentiation and T cell differentiation medium (T-Diff)
Learn More →

GLOBAL SHOWCASE
Theater B

12:15–12:30
Modernizing Safety Testing: Accelerating Microbiology for Advanced Therapies
Learn More →

12:30–13:00
The Lakhesys Benchtop Cell Factorytm: Demonstrating the Potential of a Novel Microfluidic Platform to Optimize and Scale CAR-T Manufacturing
Learn More →

13:00–13:15
Demonstrating rapid and reproducible automated flow cytometry for cell therapy QC across multiple assays, samples types, and instruments
Learn More →

13:15–13:45
Evaluation of the Corning Ascent Fixed Bed Bioreactor System for the Adherent Expansion of Human Induced Pluripotent Stem Cells
Learn More →

13:00

13:45-15:15

14:00

14:30

15:00

15:30

15:15-15:45

COFFEE BREAK
in Exhibit Hall

GLOBAL SHOWCASE
Theater A

15:15–15:30
“StemFit™” Supports Customers’ Development of Regenerative Medicine Through the Cutting-Edge Technologies
Learn More →

15:30–15:45
Non-Viral Delivery of Complex Cargos for Large-Scale T Cell Manufacturing
Learn More →

GLOBAL SHOWCASE
Theater B

15:15–15:30
Revolutionizing Large-Scale MSC Manufacturing: 3D FloTrix Technology with Dissolvable Microcarriers and Automation for the Future of Cell Therapy
Learn More →

15:30–15:45
Innovation In Container Closure Systems and Aseptic Processing for ATMPs
Learn More →

15:45–16:45
TRANSLATION TO CLINIC

CONCURRENT

Presenting Dendritic Cells: Clinical Trial Insights and Therapeutic Advances

15:45–16:45
TRANSLATION TO CLINIC

CONCURRENT

From "Bespoke" to "Off-the-Shelf" Stem Cell-Based Therapies: The Next Steps in Clinical Advancement

15:45–16:45
TRANSLATION TO CLINIC

CONCURRENT

Pushing the Frontiers of First in Human Gene Modification Therapies

15:45–16:45
ORAL ABSTRACT

Process Development & Manufacturing #1

Mesenchymal Stem / Stromal Cells #2

15:45–16:45
LAB PRACTICE ESSENTIALS

Building a New Processing Facility: Plans, Challenges, and Solutions

15:45–16:45
COGS & BUSINESS MODELS

The Pharma Perspective - What Are the CGT Technologies and Therapies of Interest?

15:45–16:45
WORKFORCE DEVELOPMENT

Is There Really a Workforce Shortage?

16:00

16:30

17:00-18:00
TRANSLATION TO CLINIC

T Cells at the Forefront: Pioneering New Avenues in Solid Tumor Therapy

17:00-18:00
TRANSLATION TO CLINIC

Immunomodulatory Mechanisms and Potency Attributes of MSC Exosomes in Disease Treatment

17:00-18:00
ORAL ABSTRACT

Regulatory Affaits, Quality Ststems, Policy, Ethics, and Patient Access

Hematopoietic Stem / Progenitor Cells and Engineering

17:00–18:00
LAB PRACTICE ESSENTIALS

Long-Term Storage of Cryopreserved Cells

17:00–18:00
CLINIC & THERAPEUTIC DEVELOPMENT

Can Cellular Start Material Predict Therapeutic Outcomes?

17:00–18:00
REGULATION & POLICY

What Stands in the Way of the RNA Revolution?

17:00

17:30

18:00

18:30

18:00-19:30

POSTER NETWORKING
RECEPTION 2

Mesenchymal Stem/Stromal Cells

Exosomes/EVs

Process Development and Manufacturing

Regulatory Affairs, Quality Systems, Policy, Ethics, and Patient Access

Tissue Engineering

GLOBAL SHOWCASE
Theater A

18:00-18:15
Enhancing the Release Testing Platform for Cell and Gene Therapies: Shifting from ddPCR to dPCR
Learn More →

18:15-18:30
From R&D to Commercial Production: Navigating Key Decisions in ATMP Manufacturing
Learn More →

18:30-18:45
The Next Frontier in Lentiviral Manufacturing
Learn More →

18:45–19:00
CD8+ Single Positive T Cell Differentiation from Human Induced Pluripotent Stem Cell with a Feeder-Free System in vitro
Learn More →

GLOBAL SHOWCASE
Theater B

18:00–18:15
A Fully Validated, Non-viral GMP Platform for the Manufacture of Engineered Cells at Clinical and Commercial Scale
Learn More →

18:15–18:30
Innovating A Xeno-Free Revolution for Cell Therapies – Human Platelet Lysate
Learn More →

19:00

19:30-21:30

EARLY STAGE PROFESSIONAL (ESP)
NETWORKING RECEPTION

by Invitation Only

Roundtrip Transportation Provided

21:30

FRIDAY, MAY 9, 2025

06:00

06:00-08:00

Separate Registration Required

07:00-08:00

CORPORATE SESSION

The Intersection of Digital Technologies and Automation in Making Cellular Therapies Mainstream:
Where We Are and Where We Need to Go

08:00

08:30

08:00–09:00
FIRST-IN-HUMAN TO CLINICAL ACCELERATION

CONCURRENT

Extending the Potential of Genetically Manipulated Cellular Therapies to Patients with Rare Disease

08:00–09:00
FIRST-IN-HUMAN TO CLINICAL ACCELERATION

CONCURRENT

Treating the Untreatable: Innovative Cell & Gene Therapy Approaches for Difficult Diseases

08:00–09:00
ORAL ABSTRACT

Exosomes / EVs

Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells

08:00–09:00
LAB PRACTICE ESSENTIALS

Validation of Cryopreserved Cells

08:00–09:00
GLOBAL CGT MARKETS

Cheaper CAR Ts - Are They as Good?

08:00–09:00
BIOPROCESSING & MANUFACTURING

iPSCs at Scale - The Path to Regulatory Approval

09:00

09:30

09:15–10:15
FIRST-IN-HUMAN TO CLINICAL ACCELERATION

CONCURRENT

Beyond Cancer: Cell Therapy for Autoimmune

09:15–10:15
FIRST-IN-HUMAN TO CLINICAL ACCELERATION

CONCURRENT

New Tips and Tricks for CGT

09:15–10:15
FIRST-IN-HUMAN TO CLINICAL ACCELERATION

CONCURRENT

In Vivo Cell Engineering: Breaking Through the Manufacturing Bottleneck

09:15–10:15
ORAL ABSTRACT

Gene Editing / Gene Therapies (AAVs, LNPs, Nucleotide-Based Therapies)

Process Development and Manufacturing #2

09:15–10:15
LAB PRACTICE ESSENTIALS

Informatics and Data Management Systems for Cell and Gene Therapy Manufacturing

09:15–10:15
CLINIC & THERAPEUTIC DEVELOPMENT

ROUNDTABLE

From Bench to Bedside - Developing a Roadmap for Large-Scale Manufacturing of iPSCs

09:15–10:15
COGS & BUSINESS MODELS

ROUNDTABLE

Leveraging Payer Frameworks to Develop Global Reimbursement Strategies

10:00

10:30

10:15-10:30

COFFEE BREAK
in Exhibit Hall

GLOBAL SHOWCASE
Theater A

10:15–10:30
Expansion of Mesenchymal Stromal Cells and Production of Extracellular Vesicles: Enhancing Yield and Reproducibility in an Animal Component-Free Bioreactor System
Learn More →

GLOBAL SHOWCASE
Theater B

10:15–10:30
Solutions for implementing rapid molecular based detection in cell therapy workflows
Learn More →

10:30-12:00

11:00

11:30

12:00

12:30

12:00-13:15

LUNCH
in Exhibit Hall, Level 1

12:30-13:00

ANNUAL GENERAL MEETING (AGM)

Society Business Meeting

12:15-13:15

CORPORATE SESSION

Purified HSC: The Path to Blood System Discovery and Regenerative Medicine

12:15-13:15

CORPORATE SESSION

Presentation Title TBD

12:15-13:15

CORPORATE SESSION

Rapid Production & Quality Control Testing: How to Get to Patient Faster?

13:00

13:30

13:15-14:45

14:00

14:30

15:00

15:30

14:45-15:00

COFFEE BREAK
in Exhibit Hall

15:00–16:00
LAUNCH & PATIENT ACCESS

CONCURRENT

Beyond the Bottleneck: Manufacturing and Supply Chain Overhaul for Real-World CGT Impact

15:00–16:00
LAUNCH & PATIENT ACCESS

CONCURRENT

Designing Evidence Strategy Beyond Regulatory Approval: Accelerating Reimbursement, Market Access and Patient Adoption

15:00–16:00
ORAL ABSTRACT

Immunotherapy #2 (CAR-T, T REG, NK CELLS, etc.)

15:00–16:00
LAB PRACTICE ESSENTIALS

Identifying Core Competencies to Advance Best Practices in CGT Manufacturing

15:00–16:00
CLINIC & THERAPEUTIC DEVELOPMENT

From Bench to Bedside: Navigating the Path of Innovative Regenerative Therapies from the Clinical Perspective

15:00–16:00
CLINIC & THERAPEUTIC DEVELOPMENT

If You Knew Then What You Know Now: Balancing Risk/Benefit for Cell Therapies Post Regulatory Approval

16:00

16:30

16:15-17:15
LAUNCH & PATIENT ACCESS

CGT Industry Trends: Using Market and Financing Insights to Avoid Commercial Failure

16:15–17:15
LAUNCH & PATIENT ACCESS

CONCURRENT

Bridging the Gap: Enabling Equitable Patient Access to Advanced Therapies

16:15–17:15
ORAL ABSTRACT

iPSC

16:15–17:15
LAB PRACTICE ESSENTIALS

Technical Transfers for Clinical Trials

16:15–17:15
REGULATION & POLICY

Are They Really Worth It? Understand Risks for Patients Receiving Genetically-Modified Immune Effector Cells

16:15–17:15
CLINIC & THERAPEUTIC DEVELOPMENT

Unlocking the Power of MSC-EVs: Factors that Impact Therapeutic Success

16:15–17:15

Early Stage Professionals (ESPs) Mentoring Summit 2025

17:00

17:15-18:15

CLOSING KEYNOTE

17:30

18:00

18:30

19:00-23:30

ISCT GALA EVENT

Separate Registration Required

Roundtrip Transportation Provided

SUPPORTED IN PART BY:

23:30

SATURDAY, MAY 10, 2025

Register Now →

Register Now →

Register Now →

Powered by Higher Logic